Tag Archives: Life Technologies

What Does This $14 Billion Merger Deal Mean For The Future Of DNA Sequencing?

By Matthew Herper, Forbes Staff In a deal that could have a big impact on the future of DNA sequencing technology, lab equipment Thermo Fisher Scientific is buying rival Life Technologies for $13.6 billion in cash and the assumption of $2.2 billion in debt. The deal values Life shares at $76 per share. That’s more than many industry analysts expected the company could get in a sale.

From: http://www.forbes.com/sites/matthewherper/2013/04/15/what-does-this-14-billion-merger-deal-mean-for-the-future-of-dna-sequencing/

Thermo Fisher to Acquire Life Technologies

By 24/7 Wall St.

Filed under:

The world’s second largest maker of laboratory equipment, Thermo Fisher Scientific Inc. (NYSE: TMO) has agree to acquire competitor Life Technologies Corp. (NASDAQ: LIFE) for $13.6 billion in cash ($76 a share). Thermo Fisher will also assume $2.2 billion in debt.

The transaction is expected to close in early 2014 and is subject to a vote by Life Technologies‘ shareholders, regulatory approvals and other customary closing conditions. Thermo Fisher has received committed financing from J.P. Morgan and Barclays and expects the payment for Life Technologies to be split with cash and debt accounting for $9.5 billion to $10 billion and equity of up to $4 billion.

The acquisition brings to Thermo Fisher an established position in the genetic sequencing business, an area in which the company has not been a player. Genetic testing and sequencing are expected to be high-growth fields in the next few years.

Last year Roche Holdings made a hostile bid for genetic testing equipment maker Illumina Inc. (NASDAQ: ILMN), which the smaller company successfully beat back. But Illumina could be back in play now because its market cap is significantly lower than Life Technologies‘ and the company may need to find a larger partner to help it compete in the market.

Life Technologies‘ shares are up 8% in premarket trading this morning, at $73.44, above the top end of its prior 52-week range of $39.73 to $68.23.

Filed under: 24/7 Wall St. Wire, Medical, Mergers & Acquisitions, Mergers and Buy Outs Tagged: ILMN, LIFE, TMO

Read | Permalink | Email this | Linking Blogs | Comments

From: http://www.dailyfinance.com/2013/04/15/thermo-fisher-to-acquire-life-technologies/

Market Minute: Dish Network Bids $25.5 Billion for Sprint Nextel

By DailyFinance Staff

Filed under: , , , ,

Getty Images

Two big takeover deals are in the works, and plunging gold prices pressure stocks.

All three of the major averages rallied by more than two percent last week, with the Dow and the S&P setting record highs along the way.

This could be a big merger Monday: Dish Network (DISH) is bidding to acquire Sprint Nextel (S). The offer – termed an informal offer and valued at more than $25 billion dollars, including debt – is intended to derail Sprint’s deal with the Japanese company Softbank.

And Thermo Fisher Scientific (TMO) has agreed to buy Life Technologies (LIFE) for more than $13 billion dollars. Both companies make laboratory equipment. Life Technologies‘ stock has jumped 25 percent since it put itself up for sale in January. At least two other groups had been considering bids.

Earnings season kicks into high gear this week. Citigroup (C) topped expectations on both earnings and revenue.
Freeport McMoRan (FCX) and Newmont Mining (NEM) are both under pressure as the price of gold tumbles more than 6 percent this morning. That’s partly because of signs of slowing growth in China.

In an effort to settle a long running anti-trust suit in Europe, Google (GOOG) has reportedly offered to change the way it operates its search engine. News reports say Google is prepared to make a greater distinction between its internet searches and those of competitors.

General Motors (GM) and Ford (F) are working together to develop more fuel efficient nine- and 10-speed transmissions for their cars. Some rivals, including Chrysler, are already there.

J.C. Penney (JCP) on Friday won a round in its court battle with Macy’s (M). The judge said Penney could temporarily sell housewares designed by Martha Stewart, while the trial continues this week.

Dell’s biggest institutional investor, Southeastern Asset Management, is stepping up its opposition to Michael Dell‘s effort to take the computer maker private. The investment firm has hired a proxy solicitation group and may contact shareholders directly.

-Produced by Drew Trachtenberg

%Gallery-183480%

Permalink | Email this | Linking Blogs | Comments

From: http://www.dailyfinance.com/on/dish-network-sprint-nextel-offer/

Life Technologies Buys KDR Biotech

By Rich Smith, The Motley Fool

Filed under:


The Wall Street Journal
calls Carlsbad, Calif.-based Life Technologies an $11 billion “company you never heard of.” As the Journal reports, a buyout group including private-equity powerhouses Blackstone , Carlyle Group , and KKR is putting together an $11 billion bid to acquire the lab research equipment manufacturer. But as it turns out, Life is doing a bit of acquiring itself.

On Friday, Life announced that it has purchased South Korean reagents distributor KDR Biotech, its own primary distributor on the Korean Peninsula, for an undisclosed sum. Life averred in a statement that it will continue selling plastic ware and similar products — which it does not itself produce but which KDR had been in the business of distributing — in South Korea going forward. Life also intends to absorb all of KDR‘s current employees, and to also take on its CEO as an “external advisor” during the integration process.

Life Technologies shares gained 1.8% on Friday, closing at $68. The company currently commands an $11.6 billion market capitalization, higher even than the Journal‘s reported buyout offer from Life’s private-equity suitors.

The article Life Technologies Buys KDR Biotech originally appeared on Fool.com.

Fool contributor Rich Smith and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
} else if (obj.attachEvent){
var r = obj.attachEvent("on"+evType, fn);
return r;
}
}

addEvent(window, "load", function(){new FoolVisualSciences();})
addEvent(window, "load", function(){new PickAd();})

var themeName = 'dailyfinance.com';
var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-24928199-1']);
_gaq.push(['_trackPageview']);

(function () {

var ga = document.createElement('script');
ga.type = 'text/javascript';
ga.async = true;
ga.src = ('https:' == document.location.protocol ? 'https://ssl'

From: http://www.dailyfinance.com/2013/04/13/news-life-technologies-buys-kdr-biotech/

And the Bidding War Winner Is …

By David Williamson, The Motley Fool

Filed under:

Shares of Life Technologies jumped in January, when the company announced it was looking for a potential buyer, and it may now be close to a decision, with solid offers having come in both from Blackstone Group and Thermo Fisher Scientific . What will this biotech decide, and how will it affect investors? In this video, Motley Fool health-care analyst David Williamson gives us a breakdown of the offers on the table, and how investors could be affected depending on the outcome.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool‘s free report “
3 Stocks That Will Help You Retire Rich
” names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. 
Click here now
 to keep reading.

The article And the Bidding War Winner Is … originally appeared on Fool.com.


David Williamson has no position in any stocks mentioned. The Motley Fool recommends Illumina and Thermo Fisher Scientific. Try any of our Foolish newsletter services free for 30 days. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
} else if (obj.attachEvent){
var r = obj.attachEvent("on"+evType, fn);
return r;
}
}

addEvent(window, "load", function(){new FoolVisualSciences();})
addEvent(window, "load", function(){new PickAd();})

var themeName = 'dailyfinance.com';
var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-24928199-1']);
_gaq.push(['_trackPageview']);

(function () {

var ga = document.createElement('script');
ga.type = 'text/javascript';

Source: FULL ARTICLE at DailyFinance

Verint and Customer Experts to Share Best Practices for Driving the Customer Experience Across Conta

By Business Wirevia The Motley Fool

Filed under:

Verint and Customer Experts to Share Best Practices for Driving the Customer Experience Across Contact Center, Branch and Back-Office Operations

MELVILLE, N.Y.–(BUSINESS WIRE)– Verint® Systems Inc. (NAS: VRNT) today announced that company experts and customers will present at several global conferences this month. Presentation topics and themes will reveal best practices in support of building customer-centric workforce optimization strategies, driving operational excellence across branch and back-office operations, developing customer experience programs, maximizing the voice of the customer, and improving employee performance with personalized guidance.


2013 SWPP Annual Conference


April 9-11; Nashville, Tennessee

Addressing its Impact 360® Workforce Optimization (WFO) implementation will be Verint customer Combined Insurance. The presentation titled “All Together Now! Taking a Unified Approach to Managing Back-Office and Contact Center Operations” will take place April 9 at 10:45 a.m. CT. Attendees will learn how this leading insurance provider applies WFO to help standardize and automate management processes across its back-office and customer management operations.

Verint’s Bill Durr—principal global solutions consultant—will join customer South Carolina Federal Credit Union in a second session titled “The Emerging Agile Workforce Strategy.” On April 10 at 9 a.m. CT, South Carolina Federal Credit Union will share how it uses an agile workforce strategy to deploy employees across traditional departmental boundaries by using a creative mix of processes, work roles and technology to help address complex scheduling requirements and challenges.


Frost & Sullivan’s 9 th Annual Customer Contact 2013, East


April 14-17; Marco Island, Florida

On April 16 at 1:20 p.m. ET., customer Life Technologies will present the session “Acting on the Voice of the Customer: Collaborating Across the Enterprise” in conjunction with Dave Capuano, vice president, marketing, Verint. The customer experience is a foundational element in acquiring, serving and creating cross- and up-selling opportunities. As a result, it’s important that organizations understand how to support it and use it to grow value. This discussion will explore the difference between problem solving for customers and creating delight, identify measurement techniques and associated metrics relevant to operations and customer experience professionals, and share important lessons learned along the way.

…read more

Source: FULL ARTICLE at DailyFinance

Illumina Announces Favorable Outcome of Its Patent Litigation Against Life Technologies, Inc.

By Business Wirevia The Motley Fool

Filed under:

Illumina Announces Favorable Outcome of Its Patent Litigation Against Life Technologies, Inc.

SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc. (NAS: ILMN) announced today that District Court Judge Cathy Ann Bencivengo of the U.S. District Court for the Southern District of California granted Illumina’s motion for summary judgment that its sequencing systems do not infringe U.S. Patent Nos. 5,616,478; 5,958,698 and 6,001,568, being asserted by Life Technologies Corporation in a lawsuit filed against Illumina in 2009. The Court ruled that, “Life Tech cannot establish, as a matter of law, that the accused Illumina systems infringe” the patents.

Jay Flatley, Illumina’s President and CEO, stated, “We are obviously very pleased with the favorable outcome of this suit. Since Life Technologies filed this patent infringement suit against Illumina in 2009, we have consistently believed and strongly argued that our sequencing technology does not infringe any of the patents Life Technologies asserted against us in this case. The federal court’s ruling has now vindicated our position. While our policy is to respect the valid and enforceable intellectual property rights of others, and take licenses where appropriate, this case demonstrates we are determined to defend vigorously any unfounded claims of infringement.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

…read more
Source: FULL ARTICLE at DailyFinance

1 of These 3 Stocks Won't Hold Its Gains

By Rich Duprey, The Motley Fool

Filed under:

The decision by the European Union over the weekend to force Cypriot bank account holders to have their savings taxed in exchange for giving the nation’s government a bailout — and the resulting vote by Cyprus‘ parliament rejecting the deal — had a chilling impact on the market. The Dow Jones Industrial Average barely moved on Tuesday, inching up just 3 points, as all eyes wondered how the financial mess would sort itself out.

If Cyprus is allowed to leave the EU, the entire structure crumbles, but taxing the bank accounts of individuals is an unprecedented maneuver that could cause bank runs in other financial unstable countries because the camel put its nose under the tent.

The three following stocks, however, were far removed from the scene of international intrigue, rising on their own merits. Yet resist the urge to high-five everyone in the cubicles next to you. Smart investors won’t celebrate until they know why their stock surged, because without a fundamental basis for the bounce, these stocks could just as quickly make the return trip down.

Company

% Gain

Pacific Biosciences

15.4%

NPS Pharmaceuticals

9.3%

8.2%

What a life!
With a potential bidding war looming for Life Technologies as possible buyers from Roche to Thermo Fisher Scientific and Danaher join a slew of PE firms weighing bids, investors looked about to see what else might be on the table and found Pacific BioSciences of California a possible target.

Life is a genetic testing company whose advanced diagnostics and consistent cash flows are considered jewels worthy of owning. PacBio is a similarly situated DNA sequencing company whose tools for biological research, including its RS system, might also suddenly be of interest to buyers if they’re eventually shut out of Life Technologies.

Roche, for example, previously considered taking over Illumina but ultimately declined, noting there were alternatives on the market for gene-sequencing technology. Presumably one of those is Life Technologies, and certainly another would be PacBio, but until bids are received for the former, a possible valuation for the latter isn’t really possible.

Take two; they’re cheap
It wasn’t a possible buyout that had shares of NPS Pharmaceuticals rocketing higher yesterday, but rather the buying back of global rights to its short-bowel syndrome drug, Gattex, and the recombinant human parathyroid hormone 1-84 that had investors bidding up its shares.

For just $50 million, NPS bought out its European distribution partner Takeda Pharmaceuticals for something that is expected to have peak sales of $350 million in the U.S. alone, in addition to what it can garner abroad. Short-bowel syndrome occurs when much of the small intestine has to be removed and the body is unable to absorb as much water and nutrients as it did previously.

NPS will pay Takeda an additional $30 million in cash or stock when sales of Gattex and 1-84 exceed $750 million annually.

Feeling sick
The …read more
Source: FULL ARTICLE at DailyFinance

The New #55 Most Shorted Nasdaq 100 Component: Life Technologies

By DividendChannel.com

The most recent short interest data was released this week by the NASDAQ for the 02/15/2013 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by “days to cover.” There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the “days to cover” metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed. …read more
Source: FULL ARTICLE at Forbes Markets

Exclusive: Life Technologies sale process cools – sources

NEW YORK (Reuters) – An $11 billion-plus sale of Life Technologies Corp is looking less likely as a gap in price expectations with the company has left potential buyer Thermo Fisher Scientific Inc skeptical about a deal while buyout firms’ offers came up short, people familiar with the matter said this week. … …read more
Source: FULL ARTICLE at Yahoo Business

A Genomics Argument About Why The NIH Is Good For Business

By Matthew Herper, Forbes Staff I wanted to find this yesterday, but didn’t get to it until today: A quote from Elaine Mardis, the Washington University in St.Louis DNA sequencing expert, about how cuts to NIH funding are hurting genomics companies like Illumina, Life Technologies, and Pacific Biosciences, even though they represent one of the few U.S. industry’s making something of value.  Strong words: …read more
Source: FULL ARTICLE at Forbes Latest